Key result
Acute myocarditis is linked to ~100% higher long-term mortality risk versus unexplained acute chest pain.
Why the study?
Acute myocarditis has variable prognosis and is often challenging to differentiate from unexplained acute chest pain in the acute setting.
Does acute myocarditis increase the risk of mortality and heart failure development compared to unexplained acute chest pain in hospitalized patients?
Cohort (n=113,726)
Yes
Does acute myocarditis increase the risk of mortality and heart failure development compared to unexplained acute chest pain in hospitalized patients?
Effect estimate: OR 2.0 (95% CI 1.69 to 2.39)
p-value: p=<0.001
Acute myocarditis is associated with significantly worse short- and long-term outcomes, including higher mortality and heart failure risk, compared to unexplained acute chest pain.
May warrant closer long-term surveillance after acute myocarditis; leaves open whether interventions improve outcomes.
AIMS: Acute myocarditis (AM) is a disease with variable prognosis, ranging from complete recovery to end-stage heart failure (HF) and death but often challenging to differentiate from unexplained acute chest pain (UCP) in the acute setting. This study examines the short-tem and long-term outcomes of AM compared with UCP, focusing on the risk of HF development. METHODS: We used the Swedish Web System for Enhancement of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies-registry to identify patients >16 years admitted to hospital between 1 January 1998 and 31 December 2018 with either AM or UCP. Patients were followed for outcomes including mortality, rehospitalisation and HF development over both short-term (30 days) and long-term periods. Cox proportional hazards models were used to compare the risks, adjusting for demographic and clinical-related factors. RESULTS: A total of 3792 patients with AM and 109 934 patients with UCP were included. Median follow-up time was 7.8 years (Q1, Q3; 3.4, 12.3). AM patients were younger compared with UCP patients, median age 37 years (Q1, Q3; 26, 52) vs 59 years (Q1, Q3; 49, 69) and more likely to be men (79.9% vs 51.4%, p<0.001). Comorbidity burden was less pronounced within the AM cohort. Chest pain was the most common presenting symptom in both groups. Mortality rate at 30 days (OR 3.75, 95% CI 1.9 to 7.3, p<0001) as well as long term (OR 2.0, 95% CI 1.69 to 2.39, p<0.001) were significantly higher in AM patients compared with UCP. AM patients were more likely to develop HF during follow-up (OR 2.3, 95% CI 1.81 to 2.93, p<0001). CONCLUSIONS: AM is associated with worse short-term and long-term outcomes compared with UCP, including a higher risk of developing HF even after the first year.
No takes yet. Share an insight, caveat, or question.
Björkenstam et al. (2025) conducted a cohort in Acute myocarditis and unexplained acute chest pain (n=113,726). Acute myocarditis vs. Unexplained acute chest pain was evaluated on Long-term all-cause mortality (OR 2.0, 95% CI 1.69 to 2.39, p=<0.001). Acute myocarditis was associated with a significantly higher risk of long-term all-cause mortality (OR 2.0) and heart failure development (OR 2.3) compared to unexplained acute chest pain.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: